Cefpodoxime how supplied

Jump to navigation Jump to search
Cefpodoxime Proxetil
VANTIN® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings
Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

VANTIN Tablets are available in the following strengths (cefpodoxime equivalent), colors, and sizes:

100 mg (light orange, elliptical, debossed with U3617) Bottles of 20 NDC 0009-3617-01 Bottles of 100 NDC 0009-3617-02 Unit dose packs of 100 NDC 0009-3617-03

200 mg (coral red, elliptical, debossed with U3618) Bottles of 20 NDC 0009-3618-01 Bottles of 100 NDC 0009-3618-02 Unit dose packs of 100 NDC 0009-3618-03

Store tablets at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].

Replace cap securely after each opening. Protect unit dose packs from excessive moisture.

VANTIN Oral Suspension provides the equivalent of 50 mg or 100 mg cefpodoxime per 5 mL suspension (when constituted as directed) and is available in lemon creme flavor in the following sizes:

50 mg/5 mL 100-mL suspension NDC 0009-3531-01 75-mL suspension NDC 0009-3531-02 50-mL suspension NDC 0009-3531-03

100 mg/5 mL 100-mL suspension NDC 0009-3615-01 75-mL suspension NDC 0009-3615-02 50-mL suspension NDC 0009-3615-03

Store unsuspended granules at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].

Directions for mixing are included on the label. After mixing, suspension should be stored in a refrigerator, 2° to 8°C (36° to 46°F). Shake well before using. Keep container tightly closed. The mixture may be used for 14 days. Discard unused portion after 14 days.


References

http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050674s015,050675s018lbl.pdf